Drug review fees in Europe to increase

03/11/2013 | In-PharmaTechnologist.com

The European Medicines Agency anticipates that fees for drug reviews will increase approximately 2.6% beginning in April, primarily to account for inflation. The EMA has also announced that it will reduce the current 75% fee reduction it offers for production of orphan drugs and use part of the additional revenue to fund salary and benefit increases.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA